NBIX


Neurocrine Biosciences Up 7.5% Despite Q4 Miss

Neurocrine Biosciences (NASDAQ: NBIX) reported weaker-than-expected Q4 results, missing both earnings and revenue estimates due to higher expenses. Despite the miss, shares of …

What Do Neurocrine’s Newly Added Risk Factors Tell Investors?

This article was originally published on TipRanks.com Neurocrine (NBIX) is an American biopharmaceutical company based in California.

Is There Any Hope for Neurocine Biosciences (NBIX) Stock? Cowen Weighs In

Neurocine Biosciences (NBIX) stock dropped about 14% Wednesday after news that its clinical trial for Ingrezza T-Force GOLD, for the treatment of Tourrette …

A Peek into Today’s Risers: BlackBerry Ltd (BBRY) and Neurocrine Biosciences, Inc. (NBIX)

BlackBerry Ltd (NASDAQ:BBRY) and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are rattling the market today with massive wins in their favor that have investors putting …

Why Neurocrine Biosciences, Inc. (NBIX) Shares Soared Today

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) investors have a smile on their faces this morning, following the news that the FDA has approved INGREZZA (valbenazine) …

FDA AdCom Meeting Cancellation for Neurocrine Biosciences, Inc. (NBIX) Ingrezza NDA Positive News: Needham Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares are on a 7% rise after the company revealed yesterday the FDA has cancelled its prior-scheduled Advisory Committee …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts